In vitro and in vivo evaluation of gentamicin sulphate-loaded PLGA nanoparticle-based film for the treatment of surgical site infection

2020 ◽  
Vol 10 (4) ◽  
pp. 1032-1043
Author(s):  
Chetan Dhal ◽  
Renuka Mishra
PLoS ONE ◽  
2019 ◽  
Vol 14 (6) ◽  
pp. e0217079 ◽  
Author(s):  
Rabia Arshad ◽  
Muhammad Farhan Sohail ◽  
Hafiz Shoaib Sarwar ◽  
Hamid Saeed ◽  
Imran Ali ◽  
...  

2012 ◽  
Vol 101 (6) ◽  
pp. 2165-2176 ◽  
Author(s):  
Gaurav Kumar ◽  
Sadhna Sharma ◽  
Nusrat Shafiq ◽  
Gopal Krishan Khuller ◽  
Samir Malhotra

2009 ◽  
Vol 4 (2) ◽  
pp. 116
Author(s):  
Patrick J Parks ◽  
Georges K Nohra ◽  
◽  

Surgical-site infections remain a significant contributor to hospital-acquired infections despite continued efforts to reduce their occurrence. Infection at the operative site is associated with high morbidity, mortality and prolonged hospitalisation. Typically, in neurosurgical cases the infection rate varies between 1 and 4%. The rise in antimicrobial resistance makes pre-operative methods to reduce surgical-site infection even more important. This is essential since hospitalised patients tend to have a higher frequency of resistant organisms, and the rise in methicillin-resistantStaphylococcus aureus(MRSA) infections has made antibiotic prophylaxis of this highly virulent organism more difficult. In this article we consider the role of pre-operative antisepsis, which aims to reduce bacterial density in the operative site, and the development of a sterile surface concept as part of an approach to reduce surgical-site infection in a neurosurgical setting. The risk of surgical-site infection is proportional to residual bacteria at the wound site, so a reduction in skin bacterial density will be associated with a concomitant reduction in surgical-site infection. The cumulativein vitroandin vivoevidence related to wound contamination and extensive clinical experience with implanted neurosurgical devices illustrate the utility of using 3M™Ioban™2 as part of an infection prevention regimen within neurosurgery.


US Neurology ◽  
2010 ◽  
Vol 06 (01) ◽  
pp. 95
Author(s):  
Patrick J Parks ◽  
Georges K Nohra ◽  
◽  

Infection at the operative site is associated with high morbidity, mortality, and prolonged hospitalization. Typically, in neurosurgical cases the infection rate varies between 1 and 4%. The rise in antimicrobial resistance makes pre-operative methods to reduce surgical-site infection even more important. This is essential since hospitalized patients tend to have a higher frequency of resistant organisms, and the rise in methicillin-resistantStaphylococcus aureus(MRSA) infections has made antibiotic prophylaxis of this highly virulent organism more difficult. In this article we consider the role of pre-operative antisepsis, which aims to reduce bacterial density in the operative site, and the development of a sterile surface concept as part of an approach to reduce surgical-site infection in a neurosurgical setting. The risk for surgical-site infection is proportional to residual bacteria at the wound site, so a reduction in skin bacterial density will be associated with a concomitant reduction in surgical-site infection. The cumulativein vitroandin vivoevidence related to wound contamination and extensive clinical experience with implanted neurosurgical devices illustrate the utility of using 3M™Ioban™2 as part of an infection prevention regimen within neurosurgery.


Planta Medica ◽  
2010 ◽  
Vol 76 (12) ◽  
Author(s):  
J Bauer ◽  
F Dehm ◽  
A Koeberle ◽  
F Pollastro ◽  
G Appendino ◽  
...  

Author(s):  
Venu Madhav K ◽  
Somnath De ◽  
Chandra Shekar Bonagiri ◽  
Sridhar Babu Gummadi

Fenofibrate (FN) is used in the treatment of hypercholesterolemia. It shows poor dissolution and poor oral bioavailability after oral administration due to high liphophilicity and low aqueous solubility. Hence, solid dispersions (SDs) of FN (FN-SDs) were develop that might enhance the dissolution and subsequently oral bioavailability. FN-SDs were prepared by solvent casting method using different carriers (PEG 4000, PEG 6000, β cyclodextrin and HP β cyclodextrin) in different proportions (0.25%, 0.5%, 0.75% and 1% w/v). FN-SDs were evaluated solubility, assay and in vitro release studies for the optimization of SD formulation. Differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD) and scanning electron microscopy (SEM) analysis was performed for crystalline and morphology analysis, respectively. Further, optimized FN-SD formulation evaluated for pharmacokinetic performance in Wistar rats, in vivo in comparison with FN suspension.  From the results, FN-SD3 and FN-SD6 have showed 102.9 ±1.3% and 105.5±3.1% drug release, respectively in 2 h. DSC and PXRD studies revealed that conversion of crystalline to amorphous nature of FN from FT-SD formulation. SEM studies revealed the change in the orientation of FN when incorporated in SDs. The oral bioavailability FN-SD3 and FN-SD6 formulations exhibited 2.5-folds and 3.1-folds improvement when compared to FN suspension as control. Overall, SD of FN could be considered as an alternative dosage form for the enhancement of oral delivery of poorly water-soluble FN.


Sign in / Sign up

Export Citation Format

Share Document